What is Sanofi business model?

The Company operates through three business segments: Pharmaceuticals, which consists of the Company’s research, development, production and marketing of medicines; Human Vaccines, which is dedicated to the development, production, marketing and sale of vaccines; and Animal Health, which includes the research.

What does Sanofi focus on?

This information is intended for U.S. residents. Sanofi is a diversified global healthcare leader, focused on developing products that meet the health needs of people. We have extensive lines of prescription medicines and vaccines, as well as consumer health products.

What are the key pillars of Sanofi its security strategy?

Our CSR strategy is organized in four pillars: Patient, Ethics, People and Planet.

What are Sanofi values?

Built on Our Core Values: Teamwork, Courage, Respect & Integrity 6 Page 7 INCLUSION & DIVERSITY PLAYBOOK Develop and promote inclusive practices to integrate diversity of thought, background and approaches to drive Sanofi culture, allowing us to… Did you know?

Who is the Chief Executive Officer of Sanofi?

Sanofi Chief Executive Officer Paul Hudson and Executive Committee members will provide a detailed overview of the company’s strategy based on four main priorities – focusing the portfolio, leading with science, accelerating efficiency, and reinventing how the company works.

What does Sanofi do to help the environment?

Integrated into the company’s Play to Win business strategy, Sanofi’s commitment to society will continue the fight against infectious diseases such as sleeping sickness and polio, while accelerating its goals to reduce the environmental impact of its products and its worldwide operations.

What are the three business units of Sanofi?

Sanofi will be structured with three core global business units to support the company’s strategy 7 – Specialty Care (immunology, rare diseases, rare blood disorders, neurology and oncology), Vaccines, and General Medicines (diabetes, cardiovascular, and established products).

Are there any de prioritized businesses at Sanofi?

Regarding de-prioritized businesses, Sanofi is announcing a discontinuation of research in diabetes and cardiovascular (DCV) and will not pursue plans to launch efpeglenatide 6.